Accessibility Menu
Grace Therapeutics logo

Grace Therapeutics(NASDAQ) ACST

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 YearN/A
1 Year-27%
1 Month+0%
N/A
Grace Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.332026-07-24
Grace Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.67%USD 2.472026-07-17
1 month+0%USD 2.332026-06-24
3 month+1.3%USD 2.302026-04-24
Year to date-32.66%USD 3.462025-12-31
1 year-27.19%USD 3.202025-07-24
Since inception-99.6%USD 588.912011-10-24

Grace Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$9.49M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 11, 2024

ACST News

GettyImages-487041629

Why Shares of Acasti Pharma Slumped Tuesday

James HalleyAug 31, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Grace Therapeutics

Grace Therapeutics develops medicines for rare diseases with few treatment options. Its main products help patients with brain bleeding and nerve pain. The company aims to improve how existing drugs are delivered to patients.

What’s in the Medicine Cabinet?

  • GTX-104 (Lead candidate): Intravenous drug for brain bleeding after aneurysm, targeting hospital patients unable to take oral medicine. (0% of revenue; pre-commercial)
  • GTX-102: Oral spray for ataxia-telangiectasia, a rare genetic disorder affecting movement and immunity. (0% of revenue; pre-commercial)
  • GTX-101: Topical spray for nerve pain after shingles, designed for easy skin application. (0% of revenue; pre-commercial)

Growth Moves: Not Just Sitting Still

  • Changed name from Acasti Pharma to Grace Therapeutics in October 2024.
  • Completed pivotal Phase 3 trial for GTX-104 in 2025, meeting main clinical goals.
  • Submitted GTX-104 for U.S. regulatory approval in June 2025.
  • Raised approximately $7.3M in September 2023 and approximately $13.7M in February 2025 through private placements.
  • Plans to license or sell GTX-102 and GTX-101 to partners for further development.

What Makes Grace Stand Out?

Grace focuses on rare diseases with few treatment options, using new ways to deliver existing drugs. Its products have special FDA status, which can mean longer market exclusivity. The company relies on outside partners for research and manufacturing, keeping its team small and focused.

Five Things You Need to Know

  • No revenue reported for QQ2 2026, QQ2 2025, or QQ2 2024.
  • Net loss was $3M in QQ2 2026, improving 47.7% from QQ2 2025.
  • Cash used in operations was $3M in QQ2 2026, a 25.6% improvement year-over-year.
  • Cash and equivalents were $20M as of June 30, 2025.
  • All products are in development; no commercial sales as of June 2025.

Bottom Line

Grace Therapeutics is a small biotech focused on rare disease treatments. The company is pre-revenue and depends on successful drug approvals and partnerships for future growth.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5

CEO

Prashant Kohli, MBA

Website

www.gracetx.com

Headquarters

Laval, QC H7E 2B5, CA

ACST Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-14.15%

Return on Capital

0.00%

Return on Assets

-13.54%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$5.62M

EBITDA

-$8.97M

Operating Cash Flow

-$8.87M

Capital Expenditure

$0.00

Free Cash Flow

-$8.87M

Cash & ST Invst.

$16.98M

Total Debt

$0.00

Grace Therapeutics Performance Analysis

Grace Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 0N/A
20242024-03-31USD 0N/A
20252025-03-31USD 0N/A
20262026-03-31USD 0N/A
Grace Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-100.0%
Q22025-09-30N/A
Q32025-12-31N/A
Q42026-03-31N/A
Grace Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -5.71256.8%
20242024-03-31USD -1.35-76.4%
20252025-03-31USD -0.79-41.3%
20262026-03-31USD -0.47-40.4%
Grace Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-290.9%
Q22025-09-3071.4%
Q32025-12-31-133.3%
Q42026-03-3157.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

32

N/A

Net Income

-$2.88M

-46.9%

EBITDA

-$5.62M

-157.3%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$16.98M

-23.3%

Total Debt

$0.00

N/A

Accounts Receivable

$20.00K

-84.1%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-13.54%

N/A

Return on Invested Capital

-20.13%

N/A

Free Cash Flow

-$1.71M

-87.5%

Operating Cash Flow

-$1.71M

-92.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IRDOpus Genetics, Inc.
$3.35+8.77%
IGXTIntelGenx Technologies Corp.
$0.17+0.00%
LUMOLumos Pharma, Inc.
$4.34+0.00%
LIANYLianBio
$0.05-3.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About ACST

What is the current price of Grace Therapeutics?

Grace Therapeutics is trading at N/A per share.

What is the 52-week range for Grace Therapeutics?

Over the past 52 weeks, Grace Therapeutics has traded between N/A and N/A.

How much debt does Grace Therapeutics have?

As of the most recent reporting period, Grace Therapeutics reported total debt of $0.00.

How much cash does Grace Therapeutics have on hand?

Grace Therapeutics reported $16.98M in cash and cash equivalents in its most recent financial results.

What is Grace Therapeutics’s dividend yield?

Grace Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services